Abercrombie & Fitch Co. (NYSE:ANF) maintained its Market Perform rating by William Blair, ahead of the company's earnings report scheduled for March 5. Dylan Carden, representing the research firm, ...
Stock analysts at William Blair raised their Q3 2025 earnings per share estimates for AZEK in a research note issued on ...
William Blair reaffirmed their positive stance on Birkenstock Holding plc (NYSE:BIRK), maintaining an Outperform rating on the company's shares. The firm's analysts highlighted Birkenstock's robust ...
William Blair, the premier global boutique with expertise in investment banking, investment management, and private wealth management, has named managing directors John Ivey and B.T. Remmert as the ...
Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...
Equities researchers at William Blair decreased their Q1 2025 earnings per share estimates for shares of Viking Therapeutics in a research note issued to investors on Wednesday, February 5th. William ...
Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...
William Blair downgraded Sprinklr (CXM) to Market Perform from Outperform without a price target after the company announced a 15% global workforce reduction. While expectations are low for the ...
William Blair last night initiated coverage of Rubrik (RBRK) with a Market Perform rating. While Rubrik’s growth runway “ooks long and its competitive moat durable,” the stock’s risk ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback